Jonathan Davis, MD, MPHS
LightNews LightNews
jonathandavishf.bsky.social
Jonathan Davis, MD, MPHS
@jonathandavishf.bsky.social
120 followers 68 following 15 posts
Director @sfhealthnetwork HF Program Zuckerberg SF General Hospital @zsfgcare @ucsfcardiology. New Dad x2! Alum @WUSTLmed⬅️ @UCSFmedicine⬅️ @cornell he/his/him
Posts Replies Media Videos
jonathandavishf.bsky.social
9/29 I start at Mercy in St. Louis!
After reflection & emotional debate, we’ve moved to STL. Working at ZSFG/UCSF has been a profound privilege. The community, patients, & colleagues gave me more than I can ever express. Please know how grateful I am to have been part of this extraordinary team.
September 29, 2025 at 3:19 AM
jonathandavishf.bsky.social
Honored beyond words to receive the 2025 @ucsfmedicine.bsky.social at @zsfgcare.bsky.social Exceptional Physician Award. It is an incredible privilege to work alongside everyone across the SFHN. Thank you!
June 9, 2025 at 1:56 AM
jonathandavishf.bsky.social
Short & sweet! Check out our review of #SGLT2i & #GLP1RA in #HeartFailure! Great work Jose Lopez & team! @ucsfcardiology.bsky.social @amitgoyalmd.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jimjanuzzi.bsky.social @sjgreene-md.bsky.social

www.uscjournal.com/articles/sho...
The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
Heart failure (HF) affects 6 million people in the US, and type 2 diabetes (T2D) is a significant risk factor for HF. Since 2008, regulatory agencies have required cardiovascular safety trials
www.uscjournal.com
May 13, 2025 at 11:14 PM
Reposted by Jonathan Davis, MD, MPHS
escardio.bsky.social
NEW! Patients versions of the #Hypertension guidelines

Need clear, reliable guidance for your patients with hypertension? The ESC has just released the patient-friendly version of its 2024 ESC Guidelines on management of elevated blood pressure and hypertension.
April 18, 2025 at 12:42 PM
jonathandavishf.bsky.social
#SGLT2i & #GLP1RA; not just for the heart... or kidneys... or diabetes! In ppl w DM2, GLP-1RAs & SGLT2is were associated w ⬇️ risk of Alzheimer disease & related dementias vs other glucose-lowering drugs. @robmentz.bsky.social @jama.com @noshreza.bsky.social @jimjanuzzi.bsky.social
ja.ma/3E3vWRn
GLP-1RAs and SGLT2is for Type 2 Diabetes and Alzheimer Disease
This population-based cohort study examines the association of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors with the risk of Alzheimer disease and related de...
ja.ma
April 16, 2025 at 9:29 PM
jonathandavishf.bsky.social
Thank you @sfchronicle.com for sharing Pamela's incredible journey from homelessness/addiction to ultimately 💓 transplant! Hopefully her story is can inspire pts & providers alike. @zsfgcare.bsky.social @ucsfhealth.bsky.social
www.sfchronicle.com/sf/article/h...
She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant
She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant.
www.sfchronicle.com
January 23, 2025 at 11:51 PM
Reposted by Jonathan Davis, MD, MPHS
jonathandavishf.bsky.social
Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink.
@natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social
nature.com/articles/s44...
New and future heart failure drugs - Nature Cardiovascular Research
Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...
nature.com
December 19, 2024 at 12:00 AM
Reposted by Jonathan Davis, MD, MPHS
jonathandavishf.bsky.social
Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social
www.jointcommission.org/resources/aw...
December 19, 2024 at 9:49 PM
jonathandavishf.bsky.social
Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social
www.jointcommission.org/resources/aw...
December 19, 2024 at 9:49 PM
jonathandavishf.bsky.social
Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink.
@natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social
nature.com/articles/s44...
New and future heart failure drugs - Nature Cardiovascular Research
Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...
nature.com
December 19, 2024 at 12:00 AM
Reposted by Jonathan Davis, MD, MPHS
jonathandavishf.bsky.social
Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation.
@jaccjournals.bsky.social
www.sciencedirect.com/science/arti...
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction
Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…
www.sciencedirect.com
December 6, 2024 at 5:32 AM
Reposted by Jonathan Davis, MD, MPHS
cardioobdoc.bsky.social
Management of Iron Deficiency in Heart Failure: Practical Considerations & Implementation of Evidence-Based Iron Supplementation

#CardioSky #JACCHF
@jaccjournals.bsky.social @robmentz.bsky.social @dranulala.bsky.social @hfsa.bsky.social @accintouch.bsky.social
www.jacc.org/doi/10.1016/...
December 9, 2024 at 8:58 PM
Reposted by Jonathan Davis, MD, MPHS
jonathandavishf.bsky.social
Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD
#UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social

vimeo.com/1032042870/2...
December 6, 2024 at 4:41 PM
jonathandavishf.bsky.social
Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD
#UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social

vimeo.com/1032042870/2...
December 6, 2024 at 4:41 PM
jonathandavishf.bsky.social
Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation.
@jaccjournals.bsky.social
www.sciencedirect.com/science/arti...
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction
Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…
www.sciencedirect.com
December 6, 2024 at 5:32 AM
jonathandavishf.bsky.social
We are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure
December 6, 2024 at 12:10 AM
jonathandavishf.bsky.social
No plans this weekend? Not too late to sign up for the 41st Annual #UCSF #ZSFG Advances in Heart Disease CME! We have a fantastic lineup ready to go!
@accintouch.bsky.social @ahascience.bsky.social @hfsa.bsky.social @aspcardio.bsky.social

virtualce.ucsf.edu/advances-in-...
41st Annual Advances in Heart Disease
virtualce.ucsf.edu
December 4, 2024 at 4:47 PM
jonathandavishf.bsky.social
Novel ExCiTe approach aimed at improving trainee recruitment into AHFTC. Great work Edan Zitelny, Rachna Kataria & team @noshreza.bsky.social
@cardionerds.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jcardfail.bsky.social @shelleyzieroth.bsky.social
onlinejcf.com/article/S107...
November 23, 2024 at 4:51 AM
Reposted by Jonathan Davis, MD, MPHS
hancardiomd.bsky.social
#Spironolactone given to patients who have undergone PCI following an #AMI has no impact on ☠️ from CV causes, or on a range of CV events including new or worsening HF ( #CLEAR SYNERGY )

www.tctmd.com/news/spirono...
@shelleywood.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social
Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY
(UPDATED) Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV events.
www.tctmd.com
November 17, 2024 at 5:11 PM
Reposted by Jonathan Davis, MD, MPHS
cardioobdoc.bsky.social
#AHA24 #CardioSky
jonathandavishf.bsky.social Jonathan Davis, MD, MPHS @jonathandavishf.bsky.social · Nov 16
1st post!

The 3 rules of #GDMTWorks for #HFrEF:
1. Start more
2.⬆️doses
3. Keep them going
#QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social
November 17, 2024 at 12:13 AM
Reposted by Jonathan Davis, MD, MPHS
drmarthagulati.bsky.social
#LBCT #SUMMIT trial #AHA24
💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity
📎 @NEJM www.nejm.org/doi/full/10....
November 16, 2024 at 3:16 PM
Reposted by Jonathan Davis, MD, MPHS
ahascience.bsky.social
BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg).

Watch this for one attendee’s take on the data.
November 16, 2024 at 6:04 PM
jonathandavishf.bsky.social
1st post!

The 3 rules of #GDMTWorks for #HFrEF:
1. Start more
2.⬆️doses
3. Keep them going
#QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social
November 16, 2024 at 6:31 PM